Bio Usawa and Yemaachi Biotech Unite to Transform HealthCare in Africa.
Diasporan biotech innovators co-develop monoclonal antibodies and genomic-driven solutions tailored for African patients. Kigali, Rwanda and Accra, Ghana — In a landmark collaboration, Bio Usawa, a pioneering biotechnology company building Africa’s monoclonal antibody development and manufacturing capacity, and Yemaachi Biotech, a leader in African cancer genomics, have joined forces to accelerate precision medicine and pharmacogenomics […]
Precision Medicine on a Budget in Africa: using existing genetic data to mitigate adverse drug reactions to conventional cancer drugs.
Alexandra Lindsey Djomkam Zune , Charles Ochieng’ Olwal, Emmanuel Agbeli , Abdoulaye Baniré Diallo , Emmanuella Amoako, Yaw Bediako , Lily Paemka. Abstract Variations in drug-metabolizing enzymes and transporters are associated with adverse drug reactions (ADRs). ADRs to cancer drugs can differ among populations owing to environmental and genetic differences. Due to limited resources and prohibitive costs associated with drug development, African countries rely on […]
Yemaachi Furthers African Cancer Research Agenda With New Breast Cancer Mutation, Research Networks
Yemaachi Biotech is preparing to expand a whole-exome sequencing pilot study, while pushing forward several other pan-African cancer research initiatives.